Skip to main content
Y-mAbs Therapeutics, Inc. (YMAB)
NASDAQ: YMAB · IEX Real-Time Price · USD
14.62
-0.22 (-1.48%)
Apr 26, 2024, 3:47 PM EDT - Market open

Y-mAbs Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year 20232022202120202019201820172016
Revenue
84.8265.2734.920.750000
Revenue Growth (YoY)
29.96%87.03%68.18%-----
Cost of Revenue
11.427.572.512.20000
Gross Profit
73.457.732.3818.550000
Selling, General & Admin
44.8660.9454.5744.7919.518.964.943.18
Research & Development
54.2291.5793.2593.763.4934.2714.3113.86
Operating Expenses
99.08152.51147.82138.488343.2319.2417.04
Operating Income
-25.67-94.81-115.43-119.94-83-43.23-19.24-17.04
Interest Expense / Income
-4.810.761.85-0.6-1.980.04-0.080
Other Expense / Income
---62.01----0.02
Pretax Income
-20.87-95.57-55.28-119.34-81.03-43.27-19.16-17.06
Income Tax
0.560000000
Net Income
-21.43-95.57-55.28-119.34-81.03-43.27-19.16-17.06
Shares Outstanding (Basic)
4444434035291914
Shares Outstanding (Diluted)
4444434035291914
Shares Change
-0.13%1.21%7.64%14.03%22.28%48.33%37.69%-
EPS (Basic)
-0.49-2.19-1.28-2.97-2.30-1.50-0.99-1.21
EPS (Diluted)
-0.49-2.19-1.28-2.97-2.30-1.50-0.99-1.21
Free Cash Flow
-27.23-75.92-41.21-91.41-75.46-41.46-15.87-11.17
Free Cash Flow Per Share
-0.62-1.74-0.95-2.28-2.15-1.44-0.82-0.79
Gross Margin
86.54%88.41%92.80%89.38%----
Operating Margin
-30.27%-145.27%-330.78%-578.00%----
Profit Margin
-25.26%-146.43%-158.39%-575.12%----
Free Cash Flow Margin
-32.11%-116.32%-118.10%-440.51%----
EBITDA
-24.94-93.97-52.64-119.54-82.84-43.2-19.24-17.06
EBITDA Margin
-29.40%-143.98%-150.85%-576.09%----
Depreciation & Amortization
0.740.840.780.40.170.0300
EBIT
-25.67-94.81-53.42-119.94-83-43.23-19.24-17.06
EBIT Margin
-30.27%-145.27%-153.09%-578.00%----
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).